• Patients must have had surgery consisting of hysterectomy and bilateral salpingo-oophorectomy. Lymph node dissection can be performed as per institutional standards. There must be no macroscopic residual disease after surgery.

• Patients must have histologically confirmed Stage I to III endometrial carcinoma which can be endometrioid, serous, clear cell, un/dedifferentiated, carcinosarcoma or mixed.

• Patients' Eastern Cooperative Group (ECOG) performance status must be 0, 1, or 2.

• HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.

• Patients' age must be ≥ 18 years.

• Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements.

• Patient is able (i.e. sufficiently fluent) and willing to complete the patient-reported outcomes (PRO) questionnaires in either English, French or a validated language

• Patients must be accessible for treatment and follow-up. Patients enrolled on this trial must be treated and followed at the participating centre

• Protocol treatment is to begin within 10 weeks of hysterectomy/bilateral salpingo-oophorectomy